A B S T R A C T Increased bronchial sensitivity to inhaled histamine in asthma is well known. The mechanism of this increased bronchial sensitivity is not known nor has it been demonstrated that isolated cells respond abnormally to histamine. Polymorphonuclear leukocytes (PMNs) provide a homogeneous cell population to study agonist response. Release of granulocyte lysosomal enzymes is inhibited by agonists increasing the PMN cyclic AMP concentration. The release of the lysosomal enzyme beta glucuronidase by serum-activated particles of zymosan was similar in PMNs isolated from normal and asthma subjects. Histamine (100-0.01 ,M) inhibited enzyme release. Except at the maximal concentration of histamine (100 ,M), the response to histamine was decreased in asthma. The inhibition of enzyme release paralleled an increase in intracellular PMN cyclic AMP. In asthma, the cyclic AMP response to histamine was reduced. The H2 antihistamine metiamide blocked histamine inhibition of lysosomal enzyme release and the increase in cyclic AMP. The effect was maximal at concentrations equimolar to those of histamine. The Hi antihistamine chlorpheniramine had no effect on histamine inhibition of granulocyte lysosomal enzyme release. A decrease in the inhibition of the release of the inflammatory lysosomal enzymes from granulocytes in asthma may contribute to an enhanced bronchial inflammatory reaction.
INTRODUCTION
Asthma is characterized by excessive irritability of the airways. In asthma, vigorous bronchoconstriction follows inhalation of histamine (1) , acetylcholine (2) , prostaglandin F2,,u (3) , and irritants (4) . Enhanced bronchoconstriction to histamine is of special interest Presented in part at the American Academy of Allergy meeting, [6] [7] [8] [9] [10] March 1976 in San Juan, Puerto Rico.
Received for publication 13 October 1976 and in revised form 4 February 1977. in view of its role as a mediator in IgE-mediated allergic asthma. Increased bronchial sensitivity to histamine in mice follows vaccination with Bordetella pertussis organisms (5) . B. pertussis-treated mice also have a decrease in the beta-adrenergic response (6) . These observations lead to the proposal that increased airway sensitivity found in asthma to various stimuli, such as histamine, was the result of diminished betaadrenergic response (7) . It was also hypothesized that decreased beta-adrenergic response in asthma was not limited to the airways but a generalized phenomenon. Both in vivo and in vitro studies with isolated tissues have found decreased beta-adrenergic response in asthma (8) (9) (10) (11) (12) . However, an altered response to histamine in isolated tissue has not yet been described in asthma (13) .
Studies from many laboratories have confirmed the existence, originally proposed by Ash and Schild (14) , that at least two types of histamine receptors were involved in the histamine response. Hi histamine receptor responses include vasodilation and smooth muscle contraction specifically blocked by the antihistamines mepyramine, diphenhydramine, and chlorpheniramine. H2 responses involve gastric acid secretion, rat uterine muscle relaxation, and guinea pig atrium contraction which are not blocked by the above antihistamines. Confirming the presence of H2 histamine receptors was possible with the discovery of new antagonists, burimamide, metiamide, and cimetidine, which specifically block the second group of responses to histamine, but not the first (15) .
Polymorphonuclear leukocyte (PMNs)l provide a homogeneous cell population for in vitro studies of responses to agonists in asthma (16) gated in vitro with incubation of granulocytes in the presence of complement activated particles of zymosan (17, 18) . Modulation of the release of these enzymes follows changes in the concentration of intracellular cyclic nucleotides (19, 20 (22) , and chopped lung preparations after antigen challenge (23) . We reported that histamine inhibition of serumactivated zymosan-induced lysosomal enzyme release from granulocytes is an H2 receptor response and parallels increases in intracellular cyclic AMP (24) . The following study found the H2 histamine response of granulocytes from patients with asthma was decreased.
METHODS
Patient selection. Adult volunteers with asthma were selected for study from the patient population of the University of Wisconsin Allergy and Immunology Clinic. The following data is based upon observations in a total of 15 patients with asthma. The patients ranged in age from 25 to 60 yr with a mean age of 35.4 yr. Asthma had been present in the patients for at least 2 yr. All have previously demonstrated reversible airway obstruction. At the time of study all patients had active but stable asthma. The clinical characteristics of the 15 asthma patients studied are presented in Table I . The severity of their asthma symptoms is classified as mild, moderate, or moderately severe. Patients with mild asthma had daily symptoms of wheezing or chest tightness that was not to the degree that it required treatment. None of these patients had used any form of bronchodilator therapy for at least 2 wk before study. The subjects with moderate severity of asthma had daily symptoms of asthma requiring routine daily use of bronchodilators (aminophylline). Two subjects were classified as being moderately severe in that they required alternate day prednisone to control their symptoms of asthma. Studies on these patients were not done on the day they had received corticosteroids. Care was also taken that all these patients were not receiving oral antihistamines or any other In experiments where neutrophils were obtained from the same subject for different experiments, care was taken that there was no change in medication and that their clinical status of asthma was similar at different study periods.
Cell preparation. Human PMNs were separated from anticoagulated blood, EDTA (2.7%), by the method of B6yum (25) , and suspended in Hanks' balanced salt solution (HBSS) in a final concentration of 3 x 106/ml (98% PMNs). Replicate samples (3 x 106 PMNs in 1 ml HBSS) were preincubated at 37°C in a shaking water bath for 5 min with cytochalasin B (CB) before the addition of 0.1 ml fresh autologous serum and 0.1 ml of the prepared zymosan (26) . Preincubation of the PMNs with the fungal metabolite CB prevents phagocytosis of the zymosan particles but not lysosomal enzyme release, which is in fact enhanced. The CB-treated PMNs resemble secretory cells. This removes the concern that the agonists may interfere with phagocytosis rather than just enzyme release. Zymosan particles were boiled in saline (10 mg/ml), washed, and resuspended in HBSS (10 mg/ml). After a 30-min incubation at 37°C, the samples were centrifuged (750 g for 10 min at 4°C) and the cell supemates were removed for enzyme determination. Total enzyme activity was determined after cell lysis with Triton X-100 (Rohm & Haas Co., Philadelphia, Pa.) (0.2%).
Pharmacological studies. In testing the effect ofhistamine on the release of beta glucuronidase (BG), the PMNs were first treated with CB and then incubated with the test compounds. In the following studies duplicate samples were performed at each experimental point. Theophylline (0.5 mM), a concentration insufficient to affect enzyme release by itself, was added and the PMNs were incubated for 15 min at 37°C. The cells were then incubated with freshly prepared histamine diphosphate for an additional 15 min at 370C before the addition of serum and zymosan. After 30 min of incubation with serum and zymosan, the samples were centrifuged and BG activity was determined in the supernate. The release of BG in the presence of histamine was compared to cells not treated. In the experiments with antihistamines, these drugs were added immediately before histamine.
Enzyme assays. The lysosomal enzyme BG in the supernate was measured after 18h of incubation with phenolphthalein glucuronic acid at 37°C and expressed as micrograms of phenolphthalein per 106 PMN per 18 h (27) . Total PMN enzyme concentration was assayed after cell rupture with 0.2% Triton X-100. Cell viability was determined by exclusion of trypan blue dye and assaying the concentration of the cytoplasmic enzyme lactate dehydrogenase in the supemate (28 
RESULTS
Enzyme release (Table II) . The total concentration of the lysosomal enzyme BG was similar in PMNs both from the normal and asthma subjects. Release of BG after 30 min of incubation with autologous serum and zymosan was not significantly less in PMNs from asthmatic subjects. In addition, BG release was similar in PMNs obtained from asthma patients receiving bronchodilators and those not having taken bronchodilators for 2 wk. A less than 4% increase in supernatant lactate dehydrogenase indicated that cell viability was maintained during these and the following incubation studies and that the release of BG was not associated with cell lysis. After the incubation procedures, greater than 95% of the PMNs excluded trypan blue.
Histamine inhibition of BG release. Maximal inhibition of BG release was achieved at 100 ,uM histamine. At this concentration the response of PMNs from asthma (Table III) and control (Table IV) subjects was similar. However, at concentrations of histamine 10-0.1 ,uM, the inhibition of lysosomal enzyme release was significantly less in PMNs of asthmatic subjects. The response to histamine in asthma was reduced approximately by a factor of 100. The decreased granulocyte response to histamine found in asthma was not affected by bronchodilator treatment and was similar in patients whether or not they required bronchodilator therapy. The results are summarized in Fig. 1 . cAMP response to histamine (Fig. 2) . The PMN cAMP response to histamine was measured and com- apparent difference in the effect of the histaminie antagonists on the normal and asthmatic cells. H2 antihistamine effect on the histamine increase (of PMN cAMP (Fig. 5) . In PMNs from the same four normal subjects and four suibjects with asthma studied above, the cAMP response to histamine was determined. Again base-line concentrations of cAMP were similar in PMNs from normal and asthma sutbjects (1.22±0.15 pmolI106 PMNs vs. 1.03±0.16 pmol/106 PMN, respectively, mean±SEM). As noted previotusly, the cAMP response to histamine was significantly less in asthma (P < 0.05). Wheni PMNs were incubated in the presence of increasing concentrations of metiamide, the cAMP response to histamine was reduced and then completely blocked at e(qtuimolar concentrations of two agents. Metiamiiide alone produced a slight increase in cAMP concentrations in PMNs from both normal and asthma stubjects. An increase in grantulocyte cAMP after incubation with metiamide was accompanied by an enhanced enzyme release. This is paradoxical in comparison to the previotis findings (Fig. 2) where a cAMP increase paralleled an inhibition of enzyme release.
The effect of propranolol on histamine inhibitiotn of enzyme release (Table V) . PMNs were inctubated with the beta-adrenergic antagonist propranolol. In the three subjects tested, the response to isoproterenol was blocked, but propranolol had no effect on histamine inhibition of BG release.
pared to histamine inhibition of BG release in five additional subjects with asthma (patients 11-15) and five additional controls (subjects [25] [26] [27] [28] [29] . At histamine concentrations of 0.01-10 ,M the inhibition of lysosomal enzyme release was again significantly less in asthma. Histamine stimulation of cAMP was also reduced in asthma and paralleled the effects of histamine on BG release. Base-line concentrations of cAMP were similar in the PMNs from normal (1.25±0.13 pmol/106 PMNs) and asthma (1.23±0.21 pmol/106 PMNs) stubjects.
Effect of antihistamines on histamine inhibition of BG release. The PMNs from four nor-mal and asthma subjects (patients 4, 9, 10, and 12) were treated with the HI antihistamine chlorpheniramine and the H2 antihistamine metiamide. At 100 ,uM chlorpheniramine alone had a small but consistent effect to inhibit the release of BG from PMNs after contact with serum-activated zymosan and also a small btut consistent enhancement of histamine inhibition of enzyme release. However, chlorpheniramine did not block the histamine inhibition of lysosomal enzyme release (Fig. 3) . Conversely, 100 4M metiamide slightly enhanced enzyme release and blocked the inhibitory effect of histamine (Fig. 4) (6) fouind that the vaccinated mice also have a dIiminished response to beta-adrenergic agonists. From these observations, Szentivanyi proposed that the hyperirritability of airways in asthma might be explained by a decreased response to beta-adrenergic stimutlation (7) . The concept that an increase in airway irritability is duie to beta-adrenergic blockade received support from the observation of McNeill that the beta-blocking drtug propranolol, cauised actute bronchoconstriction in asthmatic subjects (31) . However, propranolol has no effect on the airway responses of normal subjects to histamine or cholinergic aerosols (32 mine will contract both the large and small airways in both normals and asthmatics (34) . These are Hi receptor responses. Mathe et al. examined the cAMP and cyclic GMP response of sensitized guinea pig lung tissue to histamine (35) . Histamine increased the levels of cAMP and also to a lesser extent cyclic GMP. Pretreatment with burimamide abolished the histamine-stimulated rise of cAMP and a Hi antihistamine diminished the effect of histamine on cyclic GMP levels. While these observations were made on whole lung preparations, it is tempting to speculate that airways have both Hi and H2 receptors with the former being predominant. Stimulation of the Hi would lead to constriction and H2 stimulation might lead to relaxation. A decrease, therefore, in the H2 receptor would possibly enhance the Hl response, and in asthma this would lead to enhanced airway constriction. Asthma subjects have a 100-fold increase in airways sensitivity to histamine as compared to normal subjects. In asthma the decrease in H2 response of the granulocyte is likewise about 100-fold.
The clinical significance of this observation may also assume relevance in the role histamine plays in modulating the inflammatory response. Histamine and the other mediators of immediate hypersensitivity are released from sensitized mast cells and basophils upon specific antigen challenge. In addition to its role as mediator ofthe anaphylactic reaction, histamine inhibits the in vitro antigen-induced release of histamine from leukocytes of allergic individuals (36) . This is a H2 receptor response (37) . If the defect in H2 receptor is generalized and found on mast cells and basophils in asthma, this could lead to an enhanced release of histamine.
Airway obstruction in asthma occurs not only from bronchial muscle contraction but also inflammatory changes in the bronchi. Granulocytes are found in the bronchial wall in individuals with mucosal edema and inflammation. A prime mediator of the inflammatory response is the lysosomal enzymes from granulocytes. A decrease in histamine inhibition of lysosomal enzyme release may be playing some factor in this bronchial inflammatory response.
